Summary
Four patients with glucagon-producing tumours of the pancreas were investigated. Fasting plasma glucagon concentrations ranged from 209–625 pmol/l. Plasma insulin concentrations were normal except in one patient, where the tumour also produced insulin (558 pmol/l). Intravenous glucose (25 g/m2) depressed the glucagon concentration in two patients, while no change was noted in the others. Intravenous arginine stimulated glucagon secretion in three patients, but not in the fourth. Intravenous somatostatin suppressed glucagon secretion in all three patients investigated. All patients had abnormally low plasma levels of individual amino acids; glucogenic and branched-chain amino acids were equally depressed. Surgical removal of the tumours led to complete recovery from dermatosis and the glucagon levels were normalized. Postoperative tests were performed in three patients. The α- cell responsiveness to iv glucose was restored. Glucose tolerance (Kg-value) was improved in one patient (0.73 to 1.65), persistently low in one patient (0.75 to 0.72) and impaired in the third patient (1.35 to 1.09). It is concluded that none of these functional tests will be of diagnostic value in cases suspected of glucagonomas. The results also show that glucose homeostasis is remarkably unaffected by the extreme hyperglucagonaemia of these patients and that hypoaminoacidaemia is an important consequence of chronic hyperglucagonaemia.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
McGavran, M.H., Unger, R.H., Recant, L., Polk, H.C., Kilo, C., Levin, M.E.: A glucagon-secreting alpha-cell carcinoma of the pancreas. N. Engl. J. Med.274, 1408–1413 (1966)
Mallinson, C.N., Bloom, S.R., Warin, A.P., Salmon, P.R., Cox, B.: A glucagonoma syndrome. Lancet1974 II, 1–5
Binnick, A.N., Spencer, S.K., Dennison, W.L., Horton, E.S.: Glucagonoma syndrome. Report of two cases and literature review. Arch. Dermatol,113, 749–754 (1977)
Bloom, S.R.: Glucagonomas and skin disease. In: Endocrinology. Proceedings of the 5th International Congress of Endocrinology. James, V.H.T. (ed.), Congress Series No.402, vol.2, pp. 350–352. Amsterdam: Excerpta Medica 1977
Holst, J.J.: Glucagonomas. In: Guthormones. Bloom, S.R. (ed.), pp. 599–604. Edinburgh: Churchill Livingstone 1977
Tiengo, A., Fedele, D., Marchiori, E., Nosadini, R., Muggeo, M.: Suppression and stimulation mechanisms controlling glucagon secretion in a case of islet-cell tumour producing glucagon; insulin and gastrin. Diabetes25, 408–412 (1976)
Boden, G., Owen, O., Rezvani, L., Elfenbein, B.L., Quickel, K.E.: An islet cell carcinoma containing glucagon and insulin. Diabetes26, 128–137 (1977)
Bang Pedersen, N., Johnsson, L., Holst, J.J.: Necrolytic migratory erythema and glucagon cell tumour of the pancreas: The glucagonoma syndrome. Acta Derm. Venereol. (Stockh.)56, 391–395 (1976)
von Schenck, H., Thorell, J.I., Berg, J., Bojs, G., Dymling, J.F., Hallengren, B., Ljungberg, O., Tibblin, S.: Metabolic studies and glucagon gel filtration pattern before and after surgery in a case of glucagonoma syndrome. Acta Med. Scand.205, 155–162 (1979)
Helland, S., Thorsen, E., Holst, J.J., Ingemansson, S.: The glucagonoma syndrome — necrolytic migratory erythema. A case. T. Norsk Laegeforen (in press)
Wilkinson, D.S.: Necrolytic migratory erythema with carcinoma of the pancreas. Trans. St. Johns Hosp. Dermatol. Soc.59, 244–250 (1973)
Sweet, R.D.: A dermatosis specifically associated with a tumour of pancreatic alpha cells. Br. J. Dermatol.90, 301–308 (1974)
Holst, J.J., Christiansen, J., Kühl, G.: The enteroglucagon response to intrajejunal infusion of glucose triglycerides and sodium chloride and its relation to jejunal inhibition of gastric acid secretion in man. Scand. J. Gastroenterol.11, 297–304 (1976)
Holst, J.J., Kreutzfeldt, M., Holm, G., Jensen, E., Poulsen, J.S.D., Sparse, Brigitte, Sparsø, B., Schmidt, A.: Absence of true pancreatic glucagon but persistence of circulating pancreatic glucagon-like immunoreactivity after pancreatectomy in pigs. Diabète Metab.4, 75–79 (1978)
von Schenck, H.: Production and characterization of an antiserum against pancreatic glucagon. Clin. Chim. Acta80, 455–460 (1977)
Albano, J.D.M., Ekins, R.P., Maritz, G., Turner, A.C.: A sensitive, precise radioimmunoassay of serum insulin relying on charcoal separation of bound and free hormone moieties. Acta Endocrinol. (Kbh.)70, 487–509 (1972)
Valverde, I., Villanueva, M.L., Lozano, I., Marco, J.: Presence of glucagon immunoreactivity in the glubulin fraction of human plasma (“big plasma glucagon”). J. Clin. Endocrinol. Metab.39, 1090–1098 (1974)
Ingemansson, S., Lunderquist, A., Holst, J.J.: Selective catheterization of the pancreatic vein for radioimmunoassay in glucagon-secreting carcinoma of the pancreas. Radiology119, 555–56 (1976)
Ingemansson, S., Holst, J.J., Larsson, L.-L, Lunderquist, A.: Localization of glucagonomas by pancreas vein catheterization and glucagon assay. Surg. Gynecol. Obstet.145, 509–516 (1977)
Lundbaek, K.: Intravenous glucose tolerance as a tool in definition and diagnosis of diabetes mellitus. Br. Med. J.1962 VI, 1507–1513
Aguilar-Parada, E., Eisentraut, A.M., Unger, R.H.: Pancreatic glucagon secretion in normal and diabetic subjects. Am. J. Med. Sci.257, 415–419 (1969)
Bilbrey, G.L., Faloona, G.R., White, M.F., Knochel, J.P., Borrotto, J.: Hyperglucagonemia of renal failure. J. Clin. Invest.53, 841–847 (1974)
Unger, R.H.: Clinical evaluation of glucagon excess and deficiency. In: Methods in investigative and diagnostic endocrinology. Berson, S.A., Yalow, R.S. (eds.), Part III, vol.2B, pp. 937–942. Amsterdam: North-Holland Publishing Company 1973
Felig, P., Wahren, J., Sherwin, R., Hendler, R.: Insulin, glucagon and somatostatin in normal physiology and diabetes mellitus. Diabetes25, 1091–1099 (1976)
Mortimer, C.H., Carr, D., Lind, T., Bloom, S.R., Mallinson, C.N., Schally, A.V., Tunbridge, W.M.G., Yeomans, L., Coy, D.H., Kastin, A., Besser, G.M., Hall, R.: Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin and growth hormone in normal, diabetic, acromegalic and hypopituitary patients. Lancet1974 I, 697–701
Marliss, E.B., Aoki, T.T., Unger, R.H., Soeldner, J. Stuart, Cahill, G.F.: Glucagon levels and metabolic effects in fasting man. J. Clin. Invest.49, 2256–2270 (1970)
Soman, W., Felig, P.: Regulation of the glucagon receptor by physiological hyperglucagonaemia. Nature272, 829–932 (1978)
Lightman, S.L., Bloom, S.R.: Cure of insulin-dependent diabetes mellitus by removal of a glucagonoma. Br. Med. J.1974 I, 367–368
Holst, J.J.: Review of the glucagonoma syndrome. Ugeskr. Laeger.137, 2627–2630 (1975)
Holst, J.J.: Possible entries to the diagnosis of a glucagon-producing tumour. In: Diagnosis and localization of gastrointestinal endocrine tumours. Christiansen, L., Nielsen, O. B., Stadil, F., Stage, J. G. (eds.). Scand. J. Gastroenterol.14, (Suppl.) (1979) (In press)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Holst, J.J., Heiland, S., Ingemannson, S. et al. Functional studies in patients with the glucagonoma syndrome. Diabetologia 17, 151–156 (1979). https://doi.org/10.1007/BF01219741
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01219741